Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
Alexander E. Perl(University of Pennsylvania), Mark J. Levis(Sidney Kimmel Cancer Center), Naoko Hosono(University of Fukui), Ellin Berman(Memorial Sloan Kettering Cancer Center), Pau Montesinos(Instituto de Salud Carlos III), Wen‐Chien Chou(National Taiwan University), Amir T. Fathi(University of Southern California), Christian Récher(Institut universitaire du cancer de Toulouse Oncopole), Jörge E. Cortes(Augusta University Health), Robert K. Stuart(Memorial Sloan Kettering Cancer Center), Nikolai A. Podoltsev, Nahla Hasabou, Fabio Ciceri(Vita-Salute San Raffaele University), Andreas Neubauer(RWTH Aachen University), Timothy S. Pardee(Atrium Health Wake Forest Baptist), Maria R. Baer(University of Maryland, Baltimore), Harry P. Erba(Michigan Center for Translational Pathology), Rebecca L. Olin(University of California, San Francisco), Celalettin Üstün(Rush University Medical Center), Richard A. Larson(Urbana University), Giovanni Martinelli(University of Bologna), Erkut Bahceci(Astellas Pharma (United States)), Chaofeng Liu(Fujian Normal University), Margaret Kasner(Thomas Jefferson University), Hisayuki Yokoyama(Sendai Medical Center), Xuan Liu(Shanghai University of Traditional Chinese Medicine), Francesco Fabbiano(San Antonio College), Sung‐Soo Yoon(Seoul National University Hospital), Stefania Paolini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Antonio Di Stasi(Università Cattolica del Sacro Cuore), Je‐Hwan Lee(Ulsan College)
Cited by 1,267